Humacyte (NASDAQ:HUMA) Earns “Buy” Rating from D. Boral Capital

Humacyte (NASDAQ:HUMA)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $25.00 price target on the stock.

Other equities analysts have also issued reports about the stock. Benchmark reaffirmed a “buy” rating on shares of Humacyte in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $13.71.

Humacyte Trading Down 0.8 %

Shares of NASDAQ HUMA traded down $0.03 during midday trading on Friday, reaching $2.94. The company’s stock had a trading volume of 1,218,429 shares, compared to its average volume of 2,257,467. The stock has a 50 day simple moving average of $4.23 and a 200-day simple moving average of $4.87. Humacyte has a fifty-two week low of $2.81 and a fifty-two week high of $9.97. The stock has a market capitalization of $369.40 million, a price-to-earnings ratio of -2.18 and a beta of 1.36.

Hedge Funds Weigh In On Humacyte

A number of hedge funds have recently bought and sold shares of the company. Concurrent Investment Advisors LLC acquired a new stake in shares of Humacyte during the 3rd quarter worth approximately $75,000. Victory Capital Management Inc. grew its stake in shares of Humacyte by 551.6% in the 3rd quarter. Victory Capital Management Inc. now owns 76,896 shares of the company’s stock valued at $418,000 after buying an additional 65,095 shares during the period. Thrivent Financial for Lutherans bought a new stake in Humacyte in the 3rd quarter valued at about $712,000. Intech Investment Management LLC acquired a new position in Humacyte during the 3rd quarter worth approximately $232,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Humacyte by 10.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 721,318 shares of the company’s stock worth $3,924,000 after acquiring an additional 66,946 shares in the last quarter. Institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.